News
Fidelio Capital partners with Alphalyse to accelerate the global roll-out of LC-MS host cell protein analytics
Published July 1 2025 at 10:30 CEST
ODENSE, Denmark, June 30, 2025 – Alphalyse, a fast-growing Danish specialist contract research organization (CRO) that has developed GMP‑validated liquid‑chromatography mass‑spectrometry (LC‑MS) assays for host‑cell‑protein (HCP) impurity testing in biologic drugs, today announces that Fidelio Capital has acquired a majority stake in the company. Alphalyse’s founders will retain a significant shareholding, establishing an ambitious partnership aimed at expanding capacity, accelerating international growth, and establishing Alphalyse as the global reference in biologic HCP impurity analysis.
The partnership comes at an exciting moment for the biologics market as the drug pipeline – particularly complex modalities – continues to expand and the limitations of legacy ELISA technology become increasingly clear. LC-MS is emerging as the method of choice for drug developers and manufacturers seeking deeper process insight and stronger regulatory compliance, a trend underlined by the new U.S. Pharmacopeia (USP) General Chapter 1132.1 and recent discussions at the BEBPA Host Cell Protein Conference, where this shift was front and center.
Alphalyse already supports customers at every development stage, from discovery to commercial release, with quantitative, reproducible HCP data that de‑risks regulatory submissions and shortens development timelines. Its GMP‑validated assays are fully in line with the new USP chapter, positioning the company to scale rapidly and set a new industry standard for HCP impurity analysis worldwide.
Thomas Kofoed, PhD, Co‑founder & CEO, Alphalyse
“Demand for precise insights into HCP impurities is growing quickly as biologics pipelines continue to expand. Fidelio’s operational expertise and global network will allow us to increase our capacity and international footprint, ensuring developers and manufacturers have the data that regulators now expect from day one.”
Theodor Bonnier, Fidelio Capital
“Alphalyse operates in an exciting high-growth segment undergoing a structural shift from ELISA to LC-MS. We are impressed by the highly automated, scalable platform the team has built and look forward to supporting their ambitious international expansion.”
About Alphalyse
Founded in 2002 and headquartered in Odense, Denmark, Alphalyse provides LC‑MS–based HCP impurity analysis to an international client base spanning small biotech to large pharmaceutical companies, CROs and CDMOs across pre‑clinical, clinical and manufacturing phases.
About Fidelio Capital
Fidelio Capital is a Swedish investment firm with offices in Stockholm and London. The firm follows a long-term, partnership-led approach and has a track record of supporting growth companies such as AniCura, Vimian and Odevo.
For more information, please visit: www.alphalyse.com and www.fideliocapital.com
Press contact
Thomas Kofoed, CEO, Alphalyse
Phone: +45 6310 6501
Email: kofoed@alphalyse.com
Talk to us
Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.